Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles
about
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioningSignaling by target of rapamycin proteins in cell growth controlTuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signalingComprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activityThe TSC1-TSC2 complex: a molecular switchboard controlling cell growthExpression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size controlRegulation of mTORC1 by PI3K signalingWhere is mTOR and what is it doing there?Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic backgroundNon-canonical functions of the tuberous sclerosis complex-Rheb signalling axisThe determinants of head and neck cancer: Unmasking the PI3K pathway mutationsZebrafish Tsc1 reveals functional interactions between the cilium and the TOR pathwayTsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesionsRenal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures.Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancerThe evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development.Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation.Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Role of the Tsc1-Tsc2 complex in signaling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombeLoss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degenerationFibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy?The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasmsMolecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphansLymphangioleiomyomatosis - a wolf in sheep's clothing.Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinomaSynaptic plasticity in mouse models of autism spectrum disorders.Mechanism of oxidative DNA damage in diabetes: tuberin inactivation and downregulation of DNA repair enzyme 8-oxo-7,8-dihydro-2'-deoxyguanosine-DNA glycosylaseFaslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells.A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.mTOR, a Potential Target to Treat Autism Spectrum Disorder.Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.Key factors in mTOR regulation.Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.
P2860
Q24293153-C6F7AA7A-9281-4826-AD1E-FF1C7876DC94Q24320102-81732578-D36D-48D3-998A-6358323A7CCEQ24522447-05B5A673-2A0E-4015-BC78-AA47B5578E14Q24536092-08953EE0-A9B9-4338-BB8D-0D1989725E39Q24540242-7B06DAFB-F833-4814-A292-0F37A70280FFQ24563018-3690191B-DE30-433B-94DB-6F468958B00FQ24645204-4D24EE7A-4003-48D9-998A-B79271D108F5Q24672066-6AE2FAD0-D505-4098-B2B2-134BE45883CBQ24679076-203C26D9-4BAD-4AD0-8DD5-339581525049Q26995791-9163C66C-A9F0-44E1-BAB8-EAAD3EC2D121Q28305068-21C84355-5126-4614-9F24-F58C3A5A376EQ28507548-813FBAEE-2ED1-48FA-AB2A-038640E55CE4Q28728348-BB4BB6D5-53CC-45A9-B1FD-D864761EFB80Q30365726-3959AD46-9A96-467D-9091-6191EAA52728Q30489319-C43BD3D2-FE87-464B-BD6A-B4D6A57FA4CAQ30497818-1FF9BB00-3C0C-470F-A257-90295C23729DQ30692065-AD24F695-FD3C-457A-9F95-82AC3D5645A3Q31126940-2CEE424B-713E-45F6-B038-DE1678039BD4Q33554443-7D3124A6-C674-461A-8582-08A103E81AA0Q33559661-945FF65F-7BE4-4EB5-89C0-5D7554F75FE8Q33566604-FD985653-C2BF-4792-9781-4056DCC6118BQ34408059-8CBBFAB8-FC63-4E0E-AE97-68976DB373E1Q34536450-77ACDF09-FDCA-44DF-8B91-3BBA83F919C4Q34615463-674023D2-01A7-456C-884B-DC35DACB3881Q34987845-1C5F06B1-C348-416C-9B98-14CD7B152555Q35099876-AEFA5EC2-A8B9-4BBA-9E56-DA3F32977A3BQ35746972-FF41F7FD-688E-4650-AF03-3649EB1BE81DQ36330644-EB3FDC82-2BB4-4E32-8FCB-02C53973D2F9Q36357766-3FD739C2-3BD4-401E-B87D-EB5E47060C8FQ36383994-E928E022-6F3C-4F32-BAB7-9A0CE745CA51Q36479094-CA56DF94-9E6F-4792-B371-0A3E0696A8AEQ36906325-EA7CB749-79F5-4498-B9B4-19BA5ABBC0FFQ37056468-A1E13AB6-8E1F-460D-9829-8D4C1C00D040Q37087123-CC07EC17-B69E-42E5-B050-29C90D75CE5FQ37213565-1B05CE66-C310-4422-A68B-73C08CF1C004Q37350523-C5643A3B-6CCA-4727-8437-65825ED73DAAQ37483111-1073F15B-848F-4D8B-8931-C72A74BD9F4FQ37613506-5C9B3CDE-F22E-4088-932F-D79F4268B0C2Q37726384-ABA50372-0D01-402B-883F-DFE7AFFFC586Q39137809-CD85091E-8EC8-4B75-8539-FC471841B0DF
P2860
Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@ast
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@en
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@en-gb
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@nl
type
label
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@ast
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@en
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@en-gb
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@nl
prefLabel
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@ast
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@en
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@en-gb
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@nl
P2093
P3181
P1433
P1476
Hamartin, the product of the t ...... alized to cytoplasmic vesicles
@en
P2093
P304
P3181
P407
P577
1998-11-01T00:00:00Z